Predictors of discontinuation of adjuvant hormone therapy in patients with breast cancer

Journal of Clinical Oncology

Volumn 33, Issue 20, 2015, Pages 2262-2269

  He, Wei ^a   Fang, Fang ^a   Varnum, Catherine ^b   Eriksson, Mikael ^a   Hall, Per ^a   Czene, Kamila ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; AROMATASE INHIBITOR; GASTROINTESTINAL AGENT; HYPNOTIC AGENT; SEDATIVE AGENT; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR ANTAGONIST;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CHARLSON COMORBIDITY INDEX; COMORBIDITY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; FAMILY HISTORY; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; AGED; BREAST NEOPLASMS; ESTROGEN THERAPY; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; OVARIAN NEOPLASMS; POLYPHARMACY; PRESCRIPTION; PROPORTIONAL HAZARDS MODEL; QUESTIONNAIRE; REGISTER; RISK FACTOR; SWEDEN; TIME;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMORBIDITY; DRUG PRESCRIPTIONS; DRUG SUBSTITUTION; ESTROGEN RECEPTOR ANTAGONISTS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; OVARIAN NEOPLASMS; POLYPHARMACY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUESTIONNAIRES; REGISTRIES; RISK FACTORS; SWEDEN; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84941367943     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.59.3673     Document Type: Article

References (40)

1. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15- year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005.
2. Davies C, Pan H, Godwin J, et al: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805-816, 2013.
3. Murphy CC, Bartholomew LK, Carpentier MY, et al: Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: A systematic review. Breast Cancer Res Treat 134: 459-478, 2012.
4. Hershman DL, Shao T, Kushi LH, et al: Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529-537, 2011.
5. van Herk-Sukel MP, van de Poll-Franse LV, Voogd AC, et al: Half of breast cancer patients discontinue tamoxifen and any endocrine treatment before the end of the recommended treatment period of 5 years: A population-based analysis. Breast Cancer Res Treat 122:843-851, 2010.
6. Owusu C, Buist DS, Field TS, et al: Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26:549-555, 2008.
7. McCowan C, Shearer J, Donnan PT, et al: Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99:1763-1768, 2008.
8. Dezentjé VO, van Blijderveen NJ, Gelderblom H, et al: Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 28:2423-2429, 2010.
9. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351:1451- 1467, 1998.
10. McCowan C, Wang S, Thompson AM, et al: The value of high adherence to tamoxifen in women with breast cancer: A community-based cohort study. Br J Cancer 109:1172-1180, 2013.
11. Burstein HJ, Prestrud AA, Seidenfeld J, et al: American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784-3796, 2010.
12. Demissie S, Silliman RA, Lash TL: Adjuvant tamoxifen: Predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19:322- 328, 2001.
13. Hershman DL, Kushi LH, Shao T, et al: Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8, 769 early-stage breast cancer patients. J Clin Oncol 28:4120-4128, 2010.
14. Neugut AI, Subar M, Wilde ET, et al: Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in women with early-stage breast cancer. J Clin Oncol 29:2534-2542, 2011.
15. Sedjo RL, Devine S: Predictors of nonadherence to aromatase inhibitors among commercially insured women with breast cancer. Breast Cancer Res Treat 125:191-200, 2011.
16. Fink AK, Gurwitz J, Rakowski W, et al: Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22:3309-3315, 2004.
17. Henry NL, Azzouz F, Desta Z, et al: Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30:936-942, 2012.
18. Kimmick G, Anderson R, Camacho F, et al: Adjuvant hormonal therapy use among insured, lowincome women with breast cancer. J Clin Oncol 27:3445-3451, 2009.
19. Barron TI, Connolly R, Bennett K, et al: Early discontinuation of tamoxifen: A lesson for oncologists. Cancer 109:832-839, 2007.
20. Hadji P, Ziller V, Kyvernitakis J, et al: Persistence in patients with breast cancer treated with tamoxifen or aromatase inhibitors: A retrospective database analysis. Breast Cancer Res Treat 138: 185-191, 2013.
21. Lin JH, Zhang SM, Manson JE: Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention. Cancer Prev Res (Phila) 4:1360-1365, 2011.
22. Lindström LS, Karlsson E, Wilking UM, et al: Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol 30: 2601-2608, 2012.
23. Wettermark B, Hammar N, Fored CM, et al: The new Swedish Prescribed Drug Register- opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16:726-735, 2007.
24. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, et al: The Swedish personal identity number: Possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 24:659-667, 2009.
25. Cheddad A, Czene K, Shepherd JA, et al: Enhancement of mammographic density measures in breast cancer risk prediction. Cancer Epidemiol Biomarkers Prev 23:1314-1323, 2014.
26. Li J, Foo JN, Schoof N, et al: Large-scale genotyping identifies a new locus at 22q13.2 associated with female breast size. J Med Genet 50:666- 673, 2013.
27. Wigertz A, Ahlgren J, Holmqvist M, et al: Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: A population-based study. Breast Cancer Res Treat 133:367-373, 2012.
28. Barlow L, Westergren K, Holmberg L, et al: The completeness of the Swedish Cancer Register: A sample survey for year 1998. Acta Oncol 48:27-33, 2009.
29. Ludvigsson JF, Andersson E, Ekbom A, et al: External review and validation of the Swedish national inpatient register. BMC Public Health 11:450, 2011.
30. Sundararajan V, Henderson T, Perry C, et al: New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol 57:1288-1294, 2004.
31. Lambert P, Royston J: Further development of flexible parametric models for survival analysis. Stata J 9:265-290, 2009.
32. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999.
33. Cuzick J, Sestak I, Cella D, et al: Treatmentemergent endocrine symptoms and the risk of breast cancer recurrence: A retrospective analysis of the ATAC trial. Lancet Oncol 9:1143-1148, 2008.
34. Stearns V, Chapman JA, Ma CX, et al: Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial. J Clin Oncol 33:265-271, 2015.
35. Mortimer JE, Flatt SW, Parker BA, et al: Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat 108:421-426, 2008.
36. Hoagland AC, Morrow GR, Bennett JM, et al: Oncologists' views of cancer patient noncompliance. Am J Clin Oncol 6:239-244, 1983.
37. Partridge AH, Wang PS, Winer EP, et al: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602-606, 2003.
38. Anders CK, Hsu DS, Broadwater G, et al: Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324-3330, 2008.
39. Hsieh KP, Chen LC, Cheung KL, et al: Interruption and non-adherence to long-term adjuvant hormone therapy is associated with adverse survival outcome of breast cancer women-an Asian population-based study. PLoS One 9:e87027, 2014.
40. Güth U, Myrick ME, Schötzau A, et al: Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: How often and how often does it work? Breast Cancer Res Treat 129:799-807, 2011.